Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
Adverum Biotechnologies (Nasdaq: ADVM) announced that its CEO, Laurent Fischer, M.D., will participate in a panel discussion at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 2:10 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM) announced that its CEO, Laurent Fischer, M.D., will participate in a panel discussion at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 2:10 p.m. ET. The discussion will focus on auditory and ophthalmology topics, highlighting Adverum's commitment to addressing unmet medical needs in ocular and rare diseases. The event will be accessible via a live webcast, with a replay available for 30 days post-event. The conference runs from March 7-9, 2022, showcasing various healthcare industry insights.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was -3.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m. ET.
The live webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for 30 days following the panel discussion.
Cowen’s 42nd Annual Health Care Conference is taking place virtually on March 7 - 9, 2022. The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
About Cowen Inc.
Cowen Inc. (Cowen) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division. Cowen’s broker dealer division offers investment banking services, equity research, sales and trading, prime brokerage, global clearing and commission management services. Cowen’s investment management division builds on Cowen’s core insights by developing differentiated, actively managed investment strategies that seek to meet the dynamic needs of our clients. Founded in 1918, the firm is headquartered in New York and has offices worldwide. Learn more at Cowen.com.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration (wet AMD). For more information, please visit www.adverum.com.
Inquiries
Anand Reddi
Vice President, Head of Corporate Strategy and External Affairs & Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
Or
Laurence Watts
Gilmartin Group
T: 619-916-7620
E: laurence@gilmartinir.com
Source: Adverum Biotechnologies, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.